• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Layoffs 100%

























My $ is on the cuts will reflect the Medicare rebates. Goodluck to those who wish to stay or leave.
IRA MFP negotiations are not having as big an impact on the company as 1st thought. And the new regime in DC may ease up a little. Aside from exposing our rebates.

Bigger issue is the Medicaid cap removal. That has huge impact on Spiriva and Jardiance. $100’s of millions. And there is no negotiating there.
 




IRA MFP negotiations are not having as big an impact on the company as 1st thought. And the new regime in DC may ease up a little. Aside from exposing our rebates.

Bigger issue is the Medicaid cap removal. That has huge impact on Spiriva and Jardiance. $100’s of millions. And there is no negotiating there.
AZ must have had a reason to pull out.